Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 6/20 | 0.34 |
| ▸ | CNR2 | P34972 | 6/20 | 0.34 |
| ▸ | FAAH | O00519 | 5/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25849437 | 0.79 | FAAH (0.43) | DNM1CNR1CNR2FAAH | |
| SCHEMBL24341855 | 0.77 | FAAH (0.44) | DNM1CNR1CNR2FAAH | |
| SCHEMBL25850274 | 0.77 | CNR1 (0.32) | CNR1CNR2 | |
| SCHEMBL25850206 | 0.76 | FAAH (0.43) | DNM1CNR1CNR2FAAH | |
| SCHEMBL21096814 | 0.75 | FAAH (0.46) | DNM1CNR1CNR2FAAH | |
| SCHEMBL26033149 | 0.74 | CA14 (0.41) | DNM1CNR1CA14 | |
| SCHEMBL25835894 | 0.73 | CA14 (0.42) | DNM1CNR1CA14 | |
| SCHEMBL24340612 | 0.73 | FAAH (0.39) | DNM1CNR1CNR2FAAH | |
| SCHEMBL25843022 | 0.72 | BCHE (0.41) | — | |
| SCHEMBL26034080 | 0.71 | FAAH (0.47) | DNM1CNR1CNR2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | DNM1 376/4885CNR1 4510/4885CNR2 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.